GB2451594A - Modulation of phosphoryl transferase activity of glutamine synthetase - Google Patents

Modulation of phosphoryl transferase activity of glutamine synthetase Download PDF

Info

Publication number
GB2451594A
GB2451594A GB0818914A GB0818914A GB2451594A GB 2451594 A GB2451594 A GB 2451594A GB 0818914 A GB0818914 A GB 0818914A GB 0818914 A GB0818914 A GB 0818914A GB 2451594 A GB2451594 A GB 2451594A
Authority
GB
United Kingdom
Prior art keywords
glutamine synthetase
modulation
transferase activity
phosphoryl transferase
phosphoryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0818914A
Other versions
GB2451594A8 (en
GB0818914D0 (en
Inventor
Colin Peter Kenyon
Christiaan Wynand Van Der Westhuyzen
Lyndon Carey Oldfield
Amanda Louise Rousseau
Christopher John Parkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council for Scientific and Industrial Research CSIR
Original Assignee
Council for Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2006/000565 external-priority patent/WO2007105023A1/en
Application filed by Council for Scientific and Industrial Research CSIR filed Critical Council for Scientific and Industrial Research CSIR
Priority to GB0818914A priority Critical patent/GB2451594A/en
Publication of GB0818914D0 publication Critical patent/GB0818914D0/en
Publication of GB2451594A publication Critical patent/GB2451594A/en
Publication of GB2451594A8 publication Critical patent/GB2451594A8/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods of screening and designing compounds as inhibitors of glutamine synthetase, including adenylylated glutamine synthetase, are provided herein. Compounds and compositions useful for the treatment, prevention, and/or amelioration of bacterial infections, including Mycobacterium tuberculosis, are also provided.

Description

GB 2451594 A continuation (71) cont (56) cont Christian Wynand Van Der Westhuyzen Pesticide Biochemistry & Physiology (2002); Vol 73, 46 Applegrein Street, Brackenhurst, pp 94-1 03, "The use of molecular modelling for Alberton 0001, South Africa comparison...", Berlicki et al Biochemistry (1994), Vol 33, pp 11184-11188, Amanda Louise Rousseau "Interactions of nucleotides with fully...", Liaw et al 9 Hathersage Close, 13A Oxford Road, Journal of Medicinal Chemistry (2005); Vol 48, pp Bedford Gardens 2007, South Africa 6340-6349, "Design, synthesis, and activity of...", Berlicki et al Christopher John Parkinson Elm Avenue, Thornhill 0001, (58) Field of Search by ISA: South Africa NT CL CO7D, C12Q, GO1N, GO6F Other: EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, (72) Inventor(s): CHEM ABS Data Cohn Peter Kenyon Christian Wynand Van Der Westhuyzen
Lyndon Carey Oldfield
Amanda Louise Rousseau Christopher John Parkinson (74) Agent and/or Address for Service: Marks & Clerk Long Acre, LONDON, WC2E 9RA, United Kingdom
GB0818914A 2006-03-15 2008-10-15 Modulation of phosphoryl transferase activity of glutamine synthetase Withdrawn GB2451594A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0818914A GB2451594A (en) 2006-03-15 2008-10-15 Modulation of phosphoryl transferase activity of glutamine synthetase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2006/000565 WO2007105023A1 (en) 2006-03-15 2006-03-15 Modulation of phosphoryl transferase activity of glutamine synthetase
GB0818914A GB2451594A (en) 2006-03-15 2008-10-15 Modulation of phosphoryl transferase activity of glutamine synthetase

Publications (3)

Publication Number Publication Date
GB0818914D0 GB0818914D0 (en) 2008-11-19
GB2451594A true GB2451594A (en) 2009-02-04
GB2451594A8 GB2451594A8 (en) 2009-02-18

Family

ID=40513972

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0818914A Withdrawn GB2451594A (en) 2006-03-15 2008-10-15 Modulation of phosphoryl transferase activity of glutamine synthetase

Country Status (1)

Country Link
GB (1) GB2451594A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
DE2741383A1 (en) * 1977-08-12 1979-02-22 Lonza Ag METHOTREXATE MANUFACTURING METHOD
US4565864A (en) * 1983-06-02 1986-01-21 Riker Laboratories, Inc. Substituted imidazo[1,2-c]pyrimidines
WO1988005437A1 (en) * 1987-01-14 1988-07-28 Co Pharma Corporation S.R.L. A process for the preparation of 9-(hydroxyalkyl)-hypoxanthines
EP0295218A1 (en) * 1987-05-08 1988-12-14 ISTITUTO FARMACOLOGICO SERONO SpA A process for the preparation of 2,4-diamino-6-(1-piperidinyl)-pyrimidine N-oxide
WO2004045539A2 (en) * 2002-11-15 2004-06-03 Regents Of The University Of California Anti-microbial agents derived from methionine sulfoximine analogues
WO2004046118A2 (en) * 2002-05-06 2004-06-03 Bayer Pharmaceuticals Corporation 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
DE2741383A1 (en) * 1977-08-12 1979-02-22 Lonza Ag METHOTREXATE MANUFACTURING METHOD
US4565864A (en) * 1983-06-02 1986-01-21 Riker Laboratories, Inc. Substituted imidazo[1,2-c]pyrimidines
WO1988005437A1 (en) * 1987-01-14 1988-07-28 Co Pharma Corporation S.R.L. A process for the preparation of 9-(hydroxyalkyl)-hypoxanthines
EP0295218A1 (en) * 1987-05-08 1988-12-14 ISTITUTO FARMACOLOGICO SERONO SpA A process for the preparation of 2,4-diamino-6-(1-piperidinyl)-pyrimidine N-oxide
WO2004046118A2 (en) * 2002-05-06 2004-06-03 Bayer Pharmaceuticals Corporation 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004045539A2 (en) * 2002-11-15 2004-06-03 Regents Of The University Of California Anti-microbial agents derived from methionine sulfoximine analogues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biochemistry (1994), Vol 33, pp 11184-11188, "Interactions of nucleotides with fully...", Liaw et al *
Biochim. & Biophys. Acta: Prot. Struct. & Mol. Enzymol. (2000); Vol 1477, pp 122-145, "Stucture-function relationships of glutamine synthetases<1>", Eisenberg et al *
Bioorganic & Medicinal Chemistry (2006); Vol 14, pp 4578-4585, "Computer-aided analysis of the...", Berlicki et al *
Journal of Medicinal Chemistry (2005); Vol 48, pp 6340-6349, "Design, synthesis, and activity of...", Berlicki et al *
Pesticide Biochemistry & Physiology (2002); Vol 73, pp 94-103, "The use of molecular modelling for comparison...", Berlicki et al *
Protein Science (1993); Vol 2, pp 800-813, "Time-resolved fluorescence and...", Atkins et al *

Also Published As

Publication number Publication date
GB2451594A8 (en) 2009-02-18
GB0818914D0 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
Walter et al. Impact of arsenite and its methylated metabolites on PARP-1 activity, PARP-1 gene expression and poly (ADP-ribosyl) ation in cultured human cells
MA29629B1 (en) INHIBITORS OF HISTONE DEACETYLASE
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
Chandak et al. Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII
Lv et al. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors
PH12019501523A1 (en) Methylmenthol derivative and cool-sensation imparter composition containing same
Lee et al. Synthetic analogs of indole-containing natural products as inhibitors of sortase A and isocitrate lyase
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
AU2006254902A8 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer&#39;s disease
UA91910C2 (en) Composition for control of diseases caused by phytopathogenous microorganisms and method for control of diseases caused by phytopathogenous microorganisms on useful plants or on propagation material thereof
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
Narukawa‐Nara et al. Aminooxy‐naphthylpropionic acid and its derivatives are inhibitors of auxin biosynthesis targeting l‐tryptophan aminotransferase: structure–activity relationships
Berber et al. Synthesis and evaluation of new phthalazine substituted β-lactam derivatives as carbonic anhydrase inhibitors
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
Buchanan et al. Spermatinamine, the first natural product inhibitor of isoprenylcysteine carboxyl methyltransferase, a new cancer target
WO2005117854A3 (en) Aryl ketone compounds and compositions for delivering active agents
Kasim et al. Enhancement of drought tolerance in Triticum aestivum L. seedlings using Azospirillum brasilense NO40 and Stenotrophomonas maltophilia B11
Dai et al. Design and synthesis of C10 modified and ring-truncated canthin-6-one analogues as effective membrane-active antibacterial agents
Niu et al. Synthesis, fungicidal activity and phloem mobility of phenazine-1-carboxylic acid-alanine conjugates
WO2008152306A3 (en) Novel peptidase substrates
WO2007008376A3 (en) Use of one or more metal carriers to selectively kill mammalian cells
EP1751272B8 (en) Production of tacrolimus (fk-506) using new streptomyces species

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)